Biomarkers for Psychiatric Drug Toxicity. Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH
|
|
- Imogene Dennis
- 5 years ago
- Views:
Transcription
1 Biomarkers for Psychiatric Drug Toxicity Oct 24, 2008 Thomas R. Insel, M.D. Director, NIMH
2 Burden of Disease (DALYs) U.S., Canada, and Western Europe years old Mental Illness* Injuries, including self-inflicted Alcohol and drug use Malignant neoplasms (cancer) Cardiovascular disease Respiratory disease Musculoskeletal disease Sense organ disease Digestive disease Source: WHO World Health Report 2002
3 Burden of Disease by Specific Illness DALYs United States, Canada, and Western Europe years old Unipolar depression Alcohol use Road traffic accidents Drug use Self-inflicted injuries Bipolar disorder Migraine Schizophrenia Hearing loss COPD Source: WHO World Health Report 2002
4 Mental Disorders: Mortality Over 30,000 suicides per year (in the U.S.) -90% related to mental illness For context: 18,000 homicides 20,000 AIDS deaths only 3 forms of cancer > 30,000
5 Public Health Impact: Early Mortality in Individuals with Major Mental Illness (MMI) Data from outpatient and inpatient clients diagnosed with MMI Average age at time of death : 56 years Increased likelihood of dying from suicide Decreased likelihood of dying from cancer Years of Potential Life Lost Average Arizona Missouri Oklahoma Rhode Island Texas Utah Adapted from Colton and Manderscheid, 2006, PrevChronic Dis
6 Average Medicine Assumes homogeneity Classic RCT Results based on group means Recommendations are generic Personalized Medicine Assumes heterogeneity Moderator trials Results focus on variance and individpatterns Recommendations are specific Implications: Clinical research based on individual risk and response
7 Personalized Medicine for Mental Disorders Mental disorders can be understood as developmental brain disorders: chronic, early onset, heterogeneous. Current treatments, at best, ameliorate symptoms, but there is variation in response, adverse events, adherence, and access.
8 Personalized Medicine: Where is the need? Depression: Highest burden of illness ages (WHO, 2002) 50-70% of pts respond to SSRIsor CBT Side-effects of medication reduce effectiveness Which treatment for which patient? Schizophrenia: Deficits precede psychosis Rx s have serious side effects, poor adherence Identifying individual risk, preemptive Rx s. Which treatment for which patient?
9 Personalized Medicine: Where is the need? PTSD: Increasing prevalence ( failure of recovery ) Rx helpful Identifying individual risk, preemptive Rx s Which treatment for which patient? Bipolar Disorder: Medical and psychiatric co-morbidities Lithium effective for some but underutilized Which treatment for which patient?
10 Approaches to Pharmacogenomics of Psychiatric Medications Absorption Individual variation in choice, Distribution response, toxicity, Central Target adherence Individual Genomic Variation Metabolism Toxicity
11 Genomics of SSRI Response Absorption and distribution Neuron, 2007 Citalopram, paroxetine, amitriptyline, venlafaxine use P-gp (P-glycoprotein) an ATP-binding cassette transporter protein encoded by ABCB1 on Chr 7
12 Genomics of SSRI Response CNS Targets SLC6A4, 5HT2a, 5HT3a, Glutamate Rec Complex Arch Gen Psych 2007
13 Inverse Sum of Ranks remission response rs p<3.7 x SNPs Ordered by Physical Position rs The allele associated with better outcome was ~7 times more common in whites than blacks Afr-Am. also had a less favorable outcome, overall, than Cauc. in this sample
14 Genomics of SSRI Response Metabolism CYP450: CYP2D6, CYP2C19, CYP3A4, CYP3A5 STAR*D data: Discovery sample:831 Validation sample: 1,046
15 Treatment-Emergent Suicidal Ideation Worrisome phenomenon that occurs in ~5% of people receiving SSRIs Led to a Black Box warning on all antidepressants in adolescents Design in STAR*D: Participants who scored 0 at baseline (before citalopram treatment) and later scored 1, 2 or 3 on the same item at least once while on citalopram (n=120) Comparison group (n=1742): all participants who denied suicidal ideation emerging during treatment
16 Odds Ratio Genomics of SSRI Response Adverse events: Treatment-emergent suicidal ideation Out of 1915 patients with depression treated with citalopram, 120 developed suicidal ideation. Lahe et al, AJP, 2007
17 Approaches to Pharmacogenomics of Psychiatric Medications Absorption Individual variation in choice, Distribution response, Central Target toxicity, adherence Individual Genomic Variation Metabolism Toxicity
18 Neuroimaging: A Predictive Biomarker? Fluoxetine Responders F9 hc Cg25 hc Cg25 pcg31 Cg25 p Non- Responders F9 hc hc F9 pcg31 Mayberg, 2006
19 MEG: A Predictive Biomarker? Zarate et al, Biol Psych, 2008
20 Defining Depression Circuits Response Pathways PF MCC Cognition (attention-appraisal-action) MF PF9/46 PM6 Par40 hc CBT MCC PCC Self-awareness insight mf9/10 of11 pacc24 na-vst amg thal mb-vta Mood state sacc25 Salience Motivation MEDS Br Med Bul 65: , 2003 Arch Gen Psych 61: a-ins hth bstem Interoception (drive-autonomic-circadian) PF P Meds Cg25 PCC BS
21 Predictors of efficacy or adverse events Clinical Data Genomic Profile Proteomic Biomarker Imaging Biomarker Biosignature
22 Pathways to Personalized Medicine Discovery Moderators Clinical history Genomics Physiology Proteomics Imaging Clinical Trial Comparative efficacy with multiple outcomes Exploratory Analysis Identify predictors - response or adverse events Development Stratify by predictor Prospective Trial Assess value of stratification Dissemination Qualification of predictor Practice guidelines
23 Research for Prevention, Recovery, and Cure
Depression. Affects 6.7% of adult population Women affected twice as much as men Leading cause of disability from all medical illnesses
Advances in Depression Research: A Report From NIMH Mayada Akil, M.D. Senior Advisor to the Director National Institute of Mental Health Depression Affects 6.7% of adult population Women affected twice
More informationNIMH Update: The State of the Science
September 11, 2014 MHA Annual Meeting NIMH Update: The State of the Science Philip Wang, MD, DrPH Deputy Director, NIMH Mortality from Medical Causes Peak 1965 1995 Current 2009 2012 Suicide Percent of
More informationPharmacogenomics of Medications for Pain and Major Depression: Promise and Peril
Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy and Health
More informationTreatment has increased over past decade
Disruptive Innovations in Clinical Neuroscience: Where will we find the next generation of therapeutics? Thomas R. Insel, M.D. Director, NIMH June 21, 2013 [Disclosures - None] Treatment has increased
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationClinical Use of Ketamine in Psychiatry
Clinical Use of Ketamine in Psychiatry C. Sophia Albott, MD, MA Assistant Professor Department of Psychiatry and Behavioral Sciences University of Minnesota Medical School November 17, 2018 Disclosure
More informationSuicide Spectrum Assessment and Interventions. Welcome to RoseEd Academy. Disclaimer
RoseEd Module 7 Suicide Spectrum Assessment and Interventions Suicide Spectrum Assessment and Interventions J. Scott Nelson MA NCC LPC CRADC Staff Education Coordinator Welcome to RoseEd Academy Disclaimer
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationViolence and Mental Illness: What do we know? What do we need? What can we do?
Violence and Mental Illness: What do we know? What do we need? What can we do? Thomas R. Insel, MD Director, NIMH February 26, 2014 2 Our most critical health problems White House Executive Order January
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationDepartment of Psychiatry
Department of Psychiatry RESEARCH WATCH March 2018 - Volume 4, Issue 3 Chief Curators: Awais Aftab & Erin Fulchiero Curators: Christine Collins Heather Wobbe Javier Ponce Terashima Prakash Mishra Rob Siedler
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationScreening for Depression and Suicide Risk Assessment
Screening for Depression and Suicide Risk Assessment Karl Rosston, LCSW Suicide Prevention Coordinator (406) 444-3349 krosston@mt.gov Updated: July, 2017 Suicide Fact Sheet Center for Disease Control WISQARS
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationMedication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015
Medication Management Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015 1 Medication Management Objectives: 1. Principles of psycho-pharmacology
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationEffective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)
Protocol Title: Depression & Generalized Anxiety Disorder Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Group
More informationCarlos A. Zarate, Jr., M.D
Performing valid analysis in sex differences and treatment response in depression vs. Multi-modal imaging and psychiatric stress testing: A strategy for translational psychopharmacology in mood disorders
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationMood Disorders-Major Depression
Mood Disorders Paula Gibbs, MD Assistant Professor Department of Psychiatry Medical Director of 5West Med-Psych University of Utah Hospitals and Clinics Mood Disorders-Major Depression Key Points for Major
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationAn Introduction to Principles and Practice July 8, Presented by
An Introduction to Principles and Practice July 8, 2011 Presented by Biomarkers in Psychiatry Jay Lombard, DO Chief Scientific Officer and Medical Director Genomind 2 Our mission is to advance the care
More informationOxleas CAMHS Dr Joanna Sales Clinical Director. Adolescent problems: Depression Deliberate Self Harm Early Intervention in Psychosis
Oxleas CAMHS Dr Joanna Sales Clinical Director Adolescent problems: Depression Deliberate Self Harm Early Intervention in Psychosis PREVALENCE At any one time, the estimated number of children and young
More informationGenomind and The Genecept Assay
Genomind and The Genecept Assay A Growing Problem of Psychiatric Conditions One in four adults, approximately 61.5 M American adults suffer from mental illness 1 ; depression will become the largest health
More informationMujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon
Mujeeb U. Shad, M.D., M.S.C.S. Associate Professor of Psychiatry Oregon Health & Science University, Portland Oregon Supervising Psychiatrist Oregon State Hospital, Salem Oregon Assurex Health Inc. has
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More information11/12/2017. How effective are treatments of psychiatric disorders in children and adolescents?
How effective are treatments of psychiatric disorders in children and adolescents? Benedetto Vitiello, M.D. Pavia, November 22, 2017 1 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationMending the Mind: treatment of the severely mentally ill
Mending the Mind: treatment of the severely mentally ill First, the bad news Mental Illness Prevalence: putting things in perspective --More than 54 million Americans have a mental disorder in any given
More informationReview: Psychosocial assessment and theories of development from N141 and Psych 101
Unit III Theory and Practice of Psychiatric Nursing REQUIRED READINGS AND ACTIVITIES Related Activities Assignments Review: Psychosocial assessment and theories of development from N141 and Psych 101 Anxiety,
More informationClinical Policy Title: Pharmacogenomic tests for psychiatric medications
Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May
More informationThey deserve personalized treatment
Your patients are unique They deserve personalized treatment New laboratory service offered by STA 2 R is a panel of genetic tests that gives prescribers answers to the clinical questions below. The test
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationTreatment of Major Depression In Adolescents. Ian M Goodyer OBE MD FRCPsych FMedSci University of Cambridge
Treatment of Major Depression In Adolescents Ian M Goodyer OBE MD FRCPsych FMedSci University of Cambridge DSM: Unipolar Major Depression Irritability/anger Depressed mood Anhedonia Cognitive disturbance
More informationDepression Disease Navigation
Depression Disease Navigation The depression disease navigation program is designed to reach out to members who have been diagnosed with major depression disorder. This is accomplished by promoting treatment
More informationManagement Of Depression And Anxiety
Management Of Depression And Anxiety CME Financial Disclosure Statement I, or an immediate family member including spouse/partner, have at present and/or have had within the last 12 months, or anticipate
More informationGenetic and environmental influences on alcohol drinking behavior
Washington University School of Medicine Digital Commons@Becker Presentations 2004: Alcoholism and the Latest Genetics and Neuroscience Findings 2004 Genetic and environmental influences on alcohol drinking
More informationLinda Carpenter, M.D.
Stress, Depression and Physical Health Linda Carpenter, M.D. Associate Professor of Psychiatry and Human Behavior and Medicine Alpert Medical School of Brown University Chief, Butler Hospital Mood Disorders
More informationNovel Treatments for Mood Disorders
Novel Treatments for Mood Disorders Michael E. Henry, MD Medical Director Bipolar Clinic and Research Program Director Somatic Therapy Massachusetts General Hospital Disclosures My spouse/partner and I
More informationPharmacogenomics and Customized Therapies in Psychiatry
Pharmacogenomics and Customized Therapies in Psychiatry Toshiyuki Someya,, MD, PhD Department of Psychiatry Niigata University Graduate School of Medical and Dental Sciences The efficacy and side effects
More informationPart I Tuberculosis (TB): the Once and Future Plague
Part I Tuberculosis (TB): the Once and Future Plague John D. McKinney Global Health Institute School of Life Sciences École Polytechnique Fédérale de Lausanne (EPFL) The American Society for Cell Biology
More informationPharmacogenomics of Antidepressant Medications
Research Reviews: Pharmacy and Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Pharmacogenomics of Antidepressant Medications Amanpreet Kooner and Inder Sehgal* California Health Sciences, University
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationRethinking trauma as a global
as a global challenge Duncan Pedersen Douglas Mental Health University Institute McGill University Autumn 2011 Outline Violence as a public health problem Traumatic injuries Global fatalities and fatal
More informationDepression in Primary Care
Outline Depression in Primary Care Mitchell D. Feldman, MD, MPhil Professor Of Medicine Director of Faculty Mentoring University of California, San Francisco Background Epidemiology and impact Chronic
More informationPro-cognitive strategies in Bipolar Disorder: Challenges and New Directions. Sophia Frangou, MD, PhD, FRCPsych Professor of Psychiatry
Pro-cognitive strategies in Bipolar Disorder: Challenges and New Directions Sophia Frangou, MD, PhD, FRCPsych Professor of Psychiatry Challenges 1. Conceptual challenges Relationship between cognitive
More informationPEDIATRIC BIPOLAR DISORDER
PEDIATRIC BIPOLAR DISORDER Swapna Deshpande, MD Clinical Assistant Professor Associate Training Director, Child/Adolescent Fellowship Program Department of Psychiatry & Behavioral Sciences University of
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More informationSetting ambitious goals for patients with depression with a focus on functional recovery
Setting ambitious goals for patients with depression with a focus on functional recovery The role of the overlooked cognitive symptoms in the treatment of depression Dr Andreas Papadopoulos Locum Consultant
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Child and Adolescent Psychiatry Residency Training, Massachusetts
More informationGenomics (HMGP 7620) Pharmacogenomics.
Genomics (HMGP 7620) Pharmacogenomics http://unlockinglifescode.org/explore/genomic-medicine/pharmacogenomics Matthew Taylor MD PhD matthew.taylor@ucdenver.edu Variety is the Spice of Life Current Model:
More informationDepression and the Role of L-methylfolate
Depression and the Role of L-methylfolate Depression is a chronic and recurrent disease affecting more than 18 million people in the United States, ranking it, along with heart disease, cancer and diabetes,
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationDisorder. Objectives. Under Recognition/ Undertreatment. Making a Diagnosis
Care Partners Primary Care Provider Lunch & Learn: Why PCPs Love Collaborative Care Presenter: Wayne Bentham, MD The advantage of the collaborative care model of depression management in primary care is
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationHazard ratio for coronary heart disease mortality for SMI patients versus controls (18-49 yrs) Hazard ratio for stroke
By Michael Dixon Contents Background to Bipolar Disorder and cardiac risk Mood stabilisers and cardiac risk factors Background to Depression and cardiac risk Antidepressants and cardiac risk factors Any
More informationMeta Analysis for Safety: Context and Examples at US FDA
Meta Analysis for Safety: Context and Examples at US FDA Mark Levenson, Ph.D. Division of Biometrics 7 Office of Biostatistics Office of Translational Sciences Center for Drug Evaluation and Research U.S.
More informationBehavioral Health Hospital and Emergency Department Health Services Utilization
Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation
More informationBrian A. Coffman, PhD
Brian A. Coffman, PhD Research Instructor Department of Psychiatry University of Pittsburgh School of Medicine UPMC Western Psychiatric Hospital Pittsburgh, PA Dr. Brian Coffman is a Research Instructor
More informationNQF Behavioral Health Project Phase II Submitted Measures
0103 Major Depressive Disorder (MDD): Diagnostic Evaluation Percentage of patients aged 18 years and older with a new diagnosis or recurrent episode of MDD who met the DSM-IV criteria during the visit
More informationPrecision Medicine in Mental Health Care
Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans
More informationPharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationCongruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States
ORIGINAL RESEARCH Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States Craig W. Colton, PhD, Ronald W. Manderscheid,
More informationCharles H. Kellner, MD
ECT: Learning From Recent Trials Charles H. Kellner, MD Professor, Department of Psychiatry Icahn School of Medicine at Mount Sinai ISCTM Philadelphia, PA 27 September, 2016 Charles H. Kellner, MD Disclosures
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationNavigating Student Mental Health Issues
Navigating Student Mental Health Issues Brian D. Saunders, MD, FACS Director of Undergraduate Surgical Education Penn State College of Medicine Trouble Shooting Your Clerkship 103 April 22, 2013 Orlando,
More informationMental Health theme. School of SOCIAL AND COMMUNITY MEDICINE. University of BRISTOL
Mental Health theme Lead investigators: (collaboration - Schools of Social & Comm Med and Experimental Psychol) David Gunnell (co-lead, Public Health / Epi), Stan Zammit (co-lead; Psychiatry), Gene Feder
More informationPsychiatric genomics 2018: what the clinician needs to know
Li_benefit VPA_benefit cbz_benefit Lam_benefit Combo_ms_benefit Olz_benefit Cloz_benefit Ris_benefit Quet_benefit Ari_benefit Zip_benefit Asen_benefit Luras_benefit Pali_benefit Fluphen_benefit Haldol_benefit
More informationDepression in Primary Care Mitchell D. Feldman, MD, MPhil Professor Of Medicine Director of Faculty Mentoring University of California, San Francisco
Epidemiology of Depression in Primary Care Depression in Primary Care Mitchell D. Feldman, MD, MPhil Professor Of Medicine Director of Faculty Mentoring University of California, San Francisco Stafford
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationTreating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
More informationDepartment of Psychiatry
Department of Psychiatry RESEARCH WATCH July 2018 Volume 4, Issue 6 Chief Curator: Erin C. Fulchiero Assistant Curators: Shanna Swaringen Javier Ponce Terashima Curators: Prakash Mishra Rob Siedler Heather
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationDepression: selective serotonin reuptake inhibitors
Depression: selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors (SSRIs) are considered first-line treatment for the majority of patients with depression. citalopram and fluoxetine
More informationClinical Policy Title: Pharmacogenomic tests for psychiatric medications
Clinical Policy Title: Pharmacogenomic tests for psychiatric medications Clinical Policy Number: 02.02.01 Effective Date: October 1, 2015 Initial Review Date: April 15, 2015 Most Recent Review Date: May
More informationAre they still doing that?
Are they still doing that? Why we still give ECT and when to refer Nicol Ferrier BSc (Hons), MD, FRCP(Ed), FRCPsych Emeritus Professor of Psychiatry Newcastle University Rates of prescribing ECT in the
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationPsychiatric genomics 2016: what the clinician needs to know
Psychiatric genomics 2016: what the clinician needs to know Roy Perlis, MD MSc Center for Experimental Drugs and Diagnostics MGH Department of Psychiatry MGH Center for Human Genetic Research rperlis@partners.org
More informationRealities of Depression in Primary Care Setting
Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have
More information